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Variants Associated with the Ankle 
Brachial Index Differ by Hispanic/
Latino Ethnic Group: a genome-
wide association study in the 
Hispanic Community Health Study/
Study of Latinos
Tamar Sofer  1,2, Leslie Emery3, Deepti Jain3, Alicia M. ellis4, Cathy C. Laurie3, 
Matthew A. Allison5, Jiwon Lee1, Nuzulul Kurniansyah1, Kathleen F. Kerr  3, 
Hector M. González6, Wassim Tarraf7, Michael H. criqui5, Leslie A. Lange8, Walter R. palmas9, 
nora franceschini10 & Christina L. Wassel11
Lower extremity peripheral artery disease (PAD) burden differs by race/ethnicity. Although familial 
aggregation and heritability studies suggest a genetic basis, little is known about the genetic 
susceptibility to PAD, especially in non-European descent populations. Genome-wide association 
studies (GWAS) of the ankle brachial index (ABI) and PAD (defined as an ABI < 0.90) have not been 
conducted in Hispanics/Latinos. We performed a GWAS of PAD and the ABI in 7,589 participants 
aged >45 years from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). We also 
performed GWAS for ABI stratified by Hispanic/Latino ethnic subgroups: Central American, Mexican, 
and South American (Mainland group), and Cuban, Dominican, and Puerto Rican (Caribbean group). We 
detected two genome-wide significant associations for the ABI in COMMD10 in Puerto Ricans, and at 
SYBU in the Caribbean group. The lead SNP rs4466200 in the COMMD10 gene had a replication p = 0.02 
for the ABI in Multi-Ethnic Study of Atherosclerosis (MESA) African Americans, but it did not replicate 
in African Americans from the Cardiovascular Health Study (CHS). In a regional look-up, a nearby SNP 
rs12520838 had Bonferroni adjusted p = 0.05 (unadjusted p = 7.5 × 10−5) for PAD in MESA Hispanics. 
Among three suggestive associations (p < 10−7) in subgroup-specific analyses, DMD on chromosome X, 
identified in Central Americans, replicated in MESA Hispanics (p = 2.2 × 10−4). None of the previously 
reported ABI and PAD associations in whites generalized to Hispanics/Latinos.
The ankle brachial index (ABI) is the ratio of systolic blood pressure in the ankle to the arm, and reflects the 
degree of atherosclerotic obstruction in the lower extremity arteries. The ABI has been the major clinical diag-
nostic criterion for peripheral artery disease (PAD) for more than 40 years1. PAD, defined either by ABI ≤ 0.90 
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or via other criteria, is associated with an increased risk for incident cardiovascular disease (CVD) events and 
mortality2–6. Even borderline ABI values (0.90–1.00) are associated with increased risk of mortality7, as well as 
mobility impairment, including inability to walk 1/4 mile or climb one flight of stairs, as well as inability to com-
plete a 6 minute walk7. The burden of PAD is greater in African-Americans and Cuban Americans compared 
to non-Hispanic whites and other Hispanic groups such as Mexican Americans8,9. However, these race/ethnic 
differences have not been explained by traditional, genetic, or novel risk factors to date10–12. Although familial 
aggregation and heritability estimates suggest a significant genetic contribution, little is known about the genetic 
susceptibility to PAD in non-European populations13–16.
GWAS conducted in European ancestry populations have identified the 9p21 locus significantly associ-
ated with ABI17, although associations were attenuated and no longer genome-wide significant after account-
ing for coronary artery disease (CAD). Additionally, a variant in TCF7L2 was significantly associated with ABI 
in a large-scale candidate gene (∼50 K SNPs) analysis of European ancestry (n = 21,000), but this association 
failed to replicate in independent samples12. No significant associations were observed in more than 7,000 
African-Americans in a candidate gene array study12. In general, previous studies have been limited by discovery 
of loci that have lacked specificity for PAD (e.g. 9p21 is also associated with CHD), a lack of racial/ethnic diversity, 
or a lack of robust independent replication of initial findings. In particular, no previous studies have examined the 
genetic variants underlying the ABI and PAD in Hispanic/Latino populations.
In this study, we sought to identify novel loci associations with ABI and PAD in a large cohort of US Hispanics/
Latinos from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) using GWAS, replicate novel 
associations in independent samples, and to study whether previously identified genetic variants in European 
ancestry generalize to Hispanics/Latinos. We also performed GWAS for ABI in subgroups based on participant 
background, using genetically estimated ancestry and self-reported ethnicity, while taking into account their 
genetic and environmental heterogeneity.
Methods
HCHS/SOL population. The HCHS/SOL18,19 is a community-based cohort study of 16,415 self-identified 
Hispanic/Latino individuals aged 18–74 years and selected from households in predefined census-block groups 
across four US field centers (Chicago, IL; Miami, FL; Bronx, NY; and San Diego, CA). The HCHS/SOL baseline 
clinical examination occurred between 2008 and 2011 and included comprehensive biological, behavioral, and 
sociodemographic assessments. This study was approved by the institutional review boards (IRBs) at each field 
center, where all participants gave written informed consent, and by the Non-Biomedical IRB at the University 
of North Carolina at Chapel Hill, to the HCHS/SOL Data Coordinating Center. See Supplementary Material 
Section 3 for a complete list of IRBs that approved this study. This research was performed in accordance with 
relevant guidelines and regulations. The current study included participants who were aged >45 with measured 
ABI, and who had given DNA consent.
The cohort includes participants who self-identified as having a Hispanic/Latino background. The largest sub-
groups are Central American, Mexican, South American (comprising the Mainland group), Cuban, Dominican, 
and Puerto Rican (comprising the Caribbean group). Genetic analysis groups were based on these self-identified 
subgroups and on genetic similarity between individuals, as described in detail in Conomos, et al.20. In brief, clus-
ters of individuals in the genetic principal components space were constructed while accounting for self-identified 
group. Therefore, these subgroups mostly overlap with self-reported background, while recovering classification 
in some individuals who did not report ethnicity, and in a few instances, assigning individuals who self-reported 
to be from one subgroup, to a different one20. Thus, we used these genetic analysis subgroups consequently, rather 
than self-reported background.
Assessment of ABI and outcomes definitions. For each of the left and right side, the ABI was calculated 
as the maximum systolic blood pressure in the posterior tibial artery or the dorsalis pedis artery in the same leg, 
divided by the maximum systolic blood pressures in the left and right brachial arteries. The overall composite 
ABI was then calculated for each participant as the minimum of the left and right side ABI. A participant was 
classified as having PAD if the overall ABI was ≤0.90. We also defined a “borderline PAD” as having either ABI 
≤1.00. These classifications are visualized in Fig. S1 in the Supplementary Information.
Inclusion and exclusions criteria and study sample. The study sample included individuals aged 45–74 
years (N = 7,662 genotyped individuals). Further exclusions were: missing ABI components of blood pressure 
data (N = 60), and primarily Asian genetic ancestry (n = 13, genetic outliers20), for a total of 7,589 individu-
als included in the primary ABI analysis. In the stratified analysis by Hispanic/Latino background group, addi-
tional 20 participants were excluded due to missing group, so final sample size numbers were: Central American 
(n = 760), Cuban (n = 1,500), Dominican (n = 700), Mexican (n = 2,619), Puerto Rican (n = 1,437), and South 
American (n = 553). For PAD and borderline PAD analyses, we excluded 192 individuals with arterial stiffness 
(ABI > 1.4), for N = 7,397 individuals included.
Genotyping and imputation. HCHS/SOL individuals who consented for participation in genetic stud-
ies were genotyped using a HCHS/SOL custom 15041502 B3 array at Illumina. This array consisted of the 
Illumina Omni 2.5 M array (HumanOmni2.5-8 v.1-1), and additional ~150,000 SNPs selected based on multiple 
1000 Genomes21 phase 1 data groups (CLM: Colombian in Medellin, Colombia); MXL: Mexican Ancestry in 
Los Angeles, California; and PUR: Puerto Rican in Puerto Rico), to increase the captured Amerindian genetic 
variation22. We applied standardized quality-assurance and quality-control (QA/QC) methods23 to generate 
recommended SNP- and sample-level quality filters, as previously described in Conomos, et al.20, who also pro-
vide comprehensive details of imputation. Following filtering for quality and informativeness (polymorphic 
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and unduplicated), 2,232,944 SNPs were carried forward for imputation and downstream association analyses. 
Imputation was performed using the complete 1000 Genome phase 1 reference panel (n = 1,092)21. Genotypes 
were first pre-phased with SHAPEIT2 (v.2.r644)24 and then imputed with IMPUTE2 (v.2.3.0)25. Only variants 
with at least two copies of the minor allele present in any of the four 1000 Genomes continental panels were 
imputed. We performed downstream association analyses on the results 27,887,661 variants, and considered only 
variants with imputation quality oevar >0.3 and MAF ≥1%.
Association testing. Since ABI had a highly skewed distribution (Fig. S1), and to prevent spurious asso-
ciations, we winsorized ABI values so that the highest 1% of the values of ABI were set to the value of the 99th 
percentile of the distribution, and the lowest 1% of the values were set to the value of the 1st percentile of the 
distribution. After winsorization, the distribution was approximately normal. As a sensitivity analysis, for the top 
results we also report results from analysis that removed individuals with ABI >1.4.
To examine the association between genetic variants and the ABI, we fit a linear mixed model adjusted for sex, 
age, study center, sampling weights (to prevent potential selection bias due to the study sampling scheme), and 
the five first principal components as fixed-effects. We also had random-effects corresponding to genetic related-
ness, household, and block unit sharing. For the binary traits of PAD and borderline PAD, we used the GMMAT 
algorithm21, which calculates the score test for each genetic variant based on a logistic mixed model. We used the 
same fixed- and random-effects as in the analysis of ABI.
For ABI, we investigated association results for variants with MAF ≥ 0.01, and (if imputed) imputation quality 
oevar ≥0.3. For the binary traits of PAD and borderline PAD, we further restricted the association results to variants 
with effective number of counts of the minor alleles, defined as effN = N × MAF × (1 − MAF) × oevar of at least 50, 
in both cases and controls. For the X-chromosome association testing, we set the count of alleles to be either 0 or 2 
in males, and we calculated the effect allele frequency by separately calculating the minor allele frequency in males 
to get pm (here count of alleles was either 0 or 1), separately in females to get pf, and combining the two as (Nmpm + 
2Nf pf)/(Nm + 2Nf), where Nm and Nf are the number of males and female individuals with measured/imputed 
genotypes at the locus, respectively. Associations were genome-wide significant if their p-value < 5 × 10−8, and we 
also investigated suggestive associations, with p-value < 10−7. In addition, for an X-chromosome association, we 
performed analysis stratified by sex, to study whether it is evidently driven by one of the sexes, or both.
Stratified analysis by hispanic/latino ethnic background. To study potential differences in genetic 
association patterns between and within subgroups, we performed a secondary analysis of ABI in which a GWAS 
was conducted separately in each of the genetic analysis subgroups. We then meta-analyzed the summary sta-
tistics from each subgroup into a Mainland group and a Caribbean group separately. We used a fixed-effects 
meta-analysis that accounts for the correlations between the groups, due to relatives and shared environment26, 
and provide the p-value from the Cochran’s Q test of heterogeneity of effect sizes across the genetic analysis 
groups. To limit the potential number of false positive associations with the increased of the multiple testing 
burden due to performing a large number of GWAS, in the stratified analyses we considered only results from 
common variants, defined as those with approximate effective count of the minor allele effN (defined above) of 
at least 250, where this threshold is defined separately in each of the subgroups, yielding potentially different 
number of SNPs in each group. For reporting subgroup results, we used the same genome-wide significance and 
suggestive thresholds as in the main analysis.
Generalization and replication analysis of discovered associations. To investigate the replication 
and generalization of findings from the stratified analysis to other populations, we tested the association of the 
index SNPs (SNPs with lowest p-value in a detected association region) with the ABI in Multi-Ethnic Study of 
Atherosclerosis (MESA)27 African Americans (N = 1,613), Hispanics/Latinos (N = 1,447), and European Americans 
(N = 2,527). In the Hispanic subgroup, 54% self-reported as Mexican descent, 12% as Dominican, 13% as Puerto 
Rican, 4% as Cuban, and 14% as Other Hispanic (primarily Central and South American groups), with 3% not 
reporting. Briefly, the MESA is a prospective population based study of European descent, African- American, 
Hispanic and Asian men and women aged 45–84 at the baseline examination in 2000–02 and designed to study 
subclinical cardiovascular disease and its progression, and risk factors that predict progression to clinically overt 
cardiovascular disease27. MESA was approved by the IRBs at each field center, where all participants gave written 
informed consent, and by the Human Subjects Division at the University of Washington, Seattle, WA, to the MESA 
Data Coordinating Center. See Supplementary Material Section 3 for complete list of IRBs approving this study.
All analyses were adjusted for age, sex, and five principal components. Since we interrogated five variants in 
three ethnic subgroups (as one of the detected SNPs was not available in MESA), the p-value criterion for replica-
tion was 0.05/15 = 0.003. Because it was previously shown to have better control of type 1 error and higher power, 
under the assumption that an association replicates only if the direction of estimated association matches between 
the discovery and replication study, we used one-sided p-values for replication testing28, with the expected direc-
tion of association in MESA depending on the direction of association in the HCHS/SOL. Therefore, if an associ-
ation had the same direction in the HCHS/SOL and the replication study, the one-sided p-value is related to the 
usual two- sided p-value by p/2. However, if the directions of estimated associations do not match, the one-sided 
p-value is (1 − p/2), where p is the two-sided p-value.
Additional replication tests were performed in the Cardiovascular Health Study (CHS) and the Atherosclerosis 
Risk In Communities (ARIC), in almost 6,000 European Americans and 749 African Americans using genotypes 
and phenotypes downloaded from dbGaP. See Section 1.8 in the Supplementary Information for description.
As an exploratory analysis, and due to the high correlation between the traits and the observed heterogeneity 
in genetic association patterns, we defined regions of 105 bp upstream and downstream of our top detected loci, 
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and recorded the lead associated SNP for each of the ABI, PAD, and borderline PAD in each of the MESA repli-
cating populations in these loci. The SNPs in these loci were restricted to those with MAF ≥ 0.05 and an imputa-
tion quality score of at least 0.8.
Results
Study population characteristics overall and by self-reported Hispanic ethnic subgroup are provided in Table 1. There 
were 7,589 individuals in the primary ABI analysis. In the PAD analysis, there were 382 affected individuals with PAD 
and 7,015 unaffected (non-PAD without arterial stiffness). In the borderline PAD, there were 2,104 affected individuals 
and 5,293 unaffected (non-PAD/borderline PAD, and without arterial stiffness). ABI distribution varied in ethnic sub-
groups with the lowest mean among Cuban Americans, and highest mean among Mexican Americans.
Heritability estimation. We estimated the heritability of ABI using Haseman-Elston regression (29; 
Supplemental Information Section 1.3). The estimated heritability of ABI was 10% (95% CI: 3% to 18%) when 
including related individuals. The estimated contribution of the environmental factors household and block 
unit to the variance of ABI was 1% (95% CI: 0% to 6%). In the analysis including only unrelated individuals 
(n = 6,856), the estimated heritability was lower, 7%, (95% CI: 0% to 16%). The environmental contribution to the 
ABI variance had similarly a low estimate, with a 95% CI including zero.
Overall pooled analysis of Hispanics/Latinos. GWAS inflation factors λgc30, were all between 0.99 and 
1.005, indicating good control of population stratification. Manhattan plots and qq-plots for overall pooled anal-
yses are provided in the Supplementary Figs S2 and S3. When examining the whole cohort, none of the variants 
were significantly associated with ABI, PAD, or borderline PAD at the genome-wide significance level.
Stratified ABI analyses by Hispanic/Latino background. Supplemental Fig. S4 displays the Manhattan 
plots the ABI stratified by Hispanic background subgroup. Table 2 provides the lead variants from six loci with 
p < 10−7 in subgroup stratified analyses for the ABI. Figures S8–S13 in the Supplementary Information provide 
regional association plots for all background subgroups for the variants reported in Table 2. For all loci identi-
fied in the stratified analysis, the heterogeneity test p was < 10−3. Further, the power to detect these association 
in the pooled analysis at the genome-wide significance level, assuming that the effect size in the group in which 
they were originally detected was the same across the population, were all >0.99. Table S1 in the Supplementary 
Information presents the PAD results for the top ABI SNPs in the subgroup-stratified analyses. Table S2 pre-
sents the pooled results for the ABI and PAD for the top ABI SNPs in the subgroup-stratified analysis. There 
were two genome-wide significant associations identified for ABI. The first locus with index SNP rs3133941 
(p = 1.8 × 10−8) in the SYBU region on chromosome 8 (Fig. 1), was identified in the meta-analysis of the three 
Caribbean subgroups: Cuban, Dominican, and Puerto Rican (n = 3,637, MAF ranging from 14% to 26%). 
The second locus, COMMD10 on chromosome 5 (Fig. 2), was identified in the analysis of Puerto-Ricans only 
(n = 1,437), with the index SNP rs4466200 (p = 3.4 × 10−9, MAF = 0.35).
Among suggestive associations with the ABI (Supplemental Figs S5–S7, Fig. 3), rs6631478 in the DMD gene on 
the X-chromosome was identified in analysis of the Central American subgroup (Fig. 3; n = 760, p = 7.0 × 10−8, 
MAF = 0.31). A sex-stratified analysis at this locus suggested that the association exists in both sexes (males 
p = 4.2 × 10−4, females p = 1.2 × 10−4). There were three additional loci with p < 10−7, driven by associations with 
common variants, including an imputed indel, and two genotyped SNPs (Table 2).
To help contextualize these findings, Figs S18 and S19 in the Supplementary Information provide power analy-
sis for the main (pooled) analysis, as well the group- and subgroup-specific GWAS, for a range of MAFs and effect 
sizes. One can see that the effect sizes required for the two genome-wide significant findings, given the analyses’ 
sample sizes and SNPs’ MAFs, are quite high: between 0.2–0.3 standard deviations (SDs) of ABI in the Caribbean 
group for the SYBU locus, and a little bit higher for the COMMD10 locus detected in the Puerto-Ricans only. 
Indeed, the effect sizes reported for these loci in Table 2 are about 0.2 SDs of ABI (SDs of ABI in the HCHS/SOL 
range from 0.090 in Mexicans and South Americans to 0.105 in Puerto-Ricans). Sensitivity analysis removing 
a handful of individuals with ABI > 1.4 from the analysis reports similar results, as reported in Table S4 in the 
Supplementary Information.
Overall 
n = 7589
Central 
American 
n = 760
South 
American 
n = 553
Mexican 
n = 2619
Puerto Rican 
n = 1437
Cuban 
n = 1500
Dominican 
n = 700
Age 55 (7) 55 (7) 55 (7) 55 (7) 56 (8) 56 (8) 55 (7)
Ankle Brachial Index 1.06 (0.13) 1.06 (0.13) 1.07 (0.12) 1.08 (0.12) 1.07 (0.15) 1.04 (0.12) 1.06 (0.13)
Male Sex 2966 (39%) 265 (35%) 207 (37%) 963 (37%) 575 (40%) 709 (47%) 242 (35%)
Systolic BP 132 (21) 132 (22) 128 (21) 127 (20) 135 (21) 135 (20) 136 (21)
Diastolic BP 78 (12) 78 (11) 75 (12) 75 (11) 79 (12) 80 (12) 81 (12)
Hypertension 3075 (41%) 295 (39%) 165 (30%) 866 (33%) 702 (49%) 715 (48%) 323 (46%)
Body Mass Index 30 (6) 31 (6) 29 (5) 30 (6) 31 (6) 29 (5) 30 (5)
Current smoker 1495 (20%) 89 (12%) 78 (14%) 381 (15%) 417 (29%) 467 (31%) 62 (9%)
Diabetes 2162 (28%) 214 (28%) 103 (19%) 784 (30%) 502 (35%) 361 (24%) 192 (27%)
Table 1. Participant Characteristics Overall and by Hispanic Ethnic Subgroup*. *Mean +/− SD or n (%).
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Subgroup Index SNP Chr Position Allele A Allele B Type EAF Beta SE p-value Het p-value Gene
Dominican rs6750426 2 15131582 G A G 0.75 0.031 0.006 7.39E-08 1.44E-06
Puerto Rican rs4466200 5 115596152 G A G 0.35 0.024 0.004 3.40E-09 <1E-06 COMMD10
Puerto Rican rs7755533 6 157626334 G A G 0.59 0.022 0.004 9.28E-08 6.67E-06 TMEM242
Cuban rs113916643 7  68415037 GA  G  I 0.73  −0.024  0.004  6.47E-0 8  4.03E-05
Central American rs6631478 X 32092380 T C G 0.69 −0.024 0.004 7.02E-08 2.41E-05 DMD
Caribbean rs3133941 8 110715932 A G I 0.74–0.86 −0.018 0.003 1.78E-08 5.24E-01 SYBU
Table 2. Significant or Suggestive Loci for the Ankle Brachial Index in Stratified Subgroup Analyses*. 
*Significant or suggestive SNPs with p < 10−7 in any of the subgroup-specific analyses, or in the meta-analysis 
of the Caribbean and the Mainland subgroups. Positions are provided in genome build 37. Allele A is the effect 
allele, EAF is the effect allele frequency, and Beta is the estimated effect of an increase in the allele count/dosage 
of allele A. Type is G when the variant is genotyped, and I when it is imputed. Het p-value is the p-values from 
the Cochran’s test of heterogeneity, adapted to the settings where there are correlated individuals between strata.
Figure 1. LocusZoom plot (top) and forest plot (bottom) of the SYBU locus, detected as associated with the 
ankle brachial index (ABI) in the Caribbean group. In the locusZoom plots, each point represents a variant, 
with location marked on the x-axis, and p-values marked as the location on the y-axis. The lead SNP is 
represented by the triangle, indicating that it is imputed. The colors of the variants correspond to the strength of 
their LD (r2) with the lead SNP, with LD estimated using the combined population of the HCHS/SOL Caribbean 
group. Circles correspond to genotyped variants, x symbols to imputed variants. The p-value of heterogeneity 
(across all HCHS/SOL genetic analysis groups) was 9.3 × 10−4. The bottom of the forest plot provides results 
from MESA replication groups.
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Replication and generalization results. Table 3 provides the replication results for both genome-wide 
significant and suggestive discovery results in the MESA cohort. Neither rs3133941 in SYBU nor rs4466200 in 
COMMD10 replicated in MESA African American, European American or Hispanic groups, but rs4466200 had 
p = 0.02 in MESA African Americans (Table 3). However, this association did not replicate in African Americans 
from CHS (Table S5 in the Supplementary Information). Rs6631478 in the DMD gene replicated in MESA 
Hispanics, p = 2.2 × 10−4 (Table 3). Rs113916643 on chromosome 7 was not available in MESA. None of the 
associations replicated in European Americans (Table S6 in the Supplementary Information).
Supplementary Table S7 reports the results from the exploratory analysis that searched for the lead SNP 
in each of the MESA replicating populations and each of the traits. For the DMD locus identified for the ABI 
that replicated in MESA Hispanics, this analysis identified rs77460337, a SNP only 14 base-pairs away from the 
HCHS/SOL Central American lead SNP with a p = 5.3 × 10−7 in the PAD results of the MESA Hispanics. This 
SNP was not available in the HCHS/SOL data. At the COMMD10 locus, rs12520838 was associated with PAD in 
MESA Hispanics (p = 7.5 × 10−5), a SNP that is 99,000 base-pairs away from the HCHS/SOL Puerto Rican lead 
variant (rs4466200); these variants are not in LD, as estimated in the HCHS/SOL.
None of the previously report associations with ABI or PAD in European descent, African-Americans or 
Japanese generalized to Hispanics/Latinos (all r-values = 1, see Supplementary Information Section 1.4 for meth-
ods and Supplementary Tables S8 and S9 for results). Additionally, Supplementary Figs S15 and S16 compare the 
Figure 2. LocusZoom plot (top) and forest plot (bottom) of the COMMD10 locus, detected as associated 
with ankle brachial index (ABI) in the Puerto Rican subgroup. In the locusZoom plot, each point represents a 
variant, with location marked on the x-axis, and p-values marked as the location on the y-axis. The lead SNP 
is represented by the diamond, indicating that it is genotyped. The colors of the variants correspond to the 
strength of their LD (r2) with the lead SNP, with LD estimated using the Puerto Rican population of the HCHS/
SOL. Circles correspond to genotyped variants, x symbols to imputed variants. The p-value of heterogeneity 
(across all HCHS/SOL genetic analysis groups was 1 × 10−10. The bottom of the forest plot provides results from 
MESA replication groups.
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effect sizes between the Hispanics/Latinos from our ABI analysis to the effect sizes in two previously published 
ABI analyses in individuals of European descent.
SYTL3 gene region. A previous candidate gene study in European ancestry participants16 reported a signif-
icant association of rs2171209 in the SYTL3 gene region on chromosome 6 with the ABI. Although this variant 
was not associated with ABI, PAD or borderline PAD in our analyses, we detected a suggestive association of 
rs317789, about 700 bp from rs2171209 and uncorrelated with rs317789, with borderline PAD (p = 7.56 × 10−7) 
in the overall pooled Hispanic/Latino HCHS/SOL analysis. To study whether this association is driven by the 
Mainland group (Central American, Mexican, South American), which has higher proportion of European 
ancestry on average, we tested the association of rs317789 with borderline PAD in the Mainland and Caribbean 
groups separately. However, there was no difference between the groups (Mainland p = 0.001, Caribbean 
p = 0.0002). Further, the association with the European descent index SNP rs2171209 was not significant in either 
the Mainland or Caribbean groups (p > 0.5 in both groups).
Functional annotation of replicated association regions. At the COMMD10 locus, the lead vari-
ant rs4466200 is in LD with 261 intronic variants (r2 ≥ 0.8) based in HCHS/SOL data, including three variants 
which have evidence for biological functionality. These include (1) rs12654321(r2 = 0.96) which lies in DNaseI 
Figure 3. LocusZoom plot (top) and forest plot (bottom) of the DMD locus, detected as suggestively associated 
with ABI in the Central American genetic analysis group. In the locusZoom plots, each point represents 
a variant, with location marked on the x-axis, and p-values marked as the location on the y-axis. The lead 
SNP is represented by the diamond, indicating that it is genotyped. The colors of the variants correspond to 
the strength of their LD (r2) with the lead SNP, with LD estimated using the Central American population 
of the HCHS/SOL. Circles correspond to genotyped variants, x symbols to imputed variants. The p-value of 
heterogeneity (across all HCHS/SOL genetic analysis groups) was 2.41 × 10−5. The bottom of the forest plot 
provides results from MESA replication groups.
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hypersensitive genomic region and is bound by transcription factor CTCF in aortic adventitial fibroblast cells, (2) 
rs1382342, which is located in a DNaseI hypersensitive site in monocytes and inflammatory macrophage cells, and 3) 
rs4921067, which overlaps enhancer-binding transcription factor CEBPB binding site in IMR90 (normal human 
lung cell line) cells. Functional annotation in the heart tissues did not identify any strong candidates for likely casual 
regulatory variants at this locus. Most of the LD proxies are reported as eQTL for the COMMD10 gene. At the 
chromosome X locus that replicated, the lead variant rs6631478 is located in the intronic region of the DMD gene 
and does not have any LD proxies (r2 ≥ 0.8 in HCHS/SOL data). Other significant and suggestive loci had no clear 
functional roles.
Colocalization analysis for the region around rs4466200. Using GTEx summary statistics we identified three 
genes in three tissues that had statistically significant eQTLs at the COMMD10 gene region, and their list of 
significantly associated SNPs overlapped with the SNPs with p-value < 0.001 in the Puerto Rican ABI analysis. 
Sections 1.6 and 2.7 in the Supplementary Information provide complete description of the analysis and results, 
and Supplementary Table S10 in the Supplementary Information provides the results. There were four analyses, 
and two SNPs were identified. Rs4466200, the lead ABI Puerto Rican SNP had the highest posterior probability in 
the co-localization analysis with atrial appendage heart tissue, with the COMMD10 gene, and in the analysis with 
the left ventricle heart tissue with the SEMA6A gene. However, these posterior probabilities were low: 0.08–0.09. 
An additional SNP in the region, rs4466200, also had higher posterior probabilities, although below our threshold 
of significance (0.75) – first, in the aortic artery tissue, with gene CTB-118N6.3 (posterior probability 0.31), and 
second, in the left ventricle heart tissue with gene COMMD10 (posterior probability 0.40).
Pathway enrichment analysis. We used GOrilla31 to search for enriched pathways based on gene scores from 
the pooled ABI analysis. Detailed methods are provided in Supplementary Information Section 1.7. After False 
Discovery Rate control (FDR), there were two pathways, both of type “function” (as annotated in GOrilla) that 
were significantly enriched (FDR q-value < 0.05): nucleosomal DNA binding (q-value = 0.002), and chromatin 
DNA binding (q-value = 0.002) pathways. Figure S17 in the Supplementary Information displays these pathways 
in a larger context of molecular function.
Discussion
We examined the genetic architecture underlying ABI and PAD in the Hispanic/Latino population using a large 
cohort of ancestrally diverse Hispanics/Latinos living in the US. We report results from GWAS of ABI, PAD, and 
borderline PAD, both between and within ethnic subgroups based on genetic background. We identified two 
genome-wide significant loci (SYBU, COMMD10) and three suggestive associations for the ABI in analyses strat-
ified by Hispanic/Latino ethnic background. However, we found no genome wide significant results in the overall 
pooled analyses of HCHS/SOL Hispanics/Latinos, perhaps due to significant genetic heterogeneity in risk for PAD 
among Hispanic/Latino subgroups8, as well as substantial differences in local and global genetic admixture among 
these groups, as suggested by differences in allele frequencies between groups in the detected association regions.
The COMMD10 locus on chromosome 5 had p-value = 0.02 in MESA African-Americans for ABI, and region-
ally replicated for PAD in MESA Hispanics (FDR p = 0.05). This SNP had smaller estimated effect size in 749 
African-Americans from CHS and replication p-value = 0.43. This could be because this is not a real signal, or due 
to low power, and difference in age distribution (CHS participants were 65 and older). COMMD10 is a member of 
the COMM domain containing proteins, and encodes a protein that inhibits and mediates NF-κB, a transcription 
factor involved in innate and adaptive immune responses, and possibly with inflammatory processes32,33. Variants 
in COMMD10 have been previously associated with multiple sclerosis33, inflammatory factors (tumor necrosis fac-
tor(TNF)-α and monocyte chemoattractant protein (MCP)-1)34, as well as chronic obstructive pulmonary disease 
(COPD) and asthma35. The functional annotation results showed COMMD10 variants overlapping putative regula-
tory regions in adventitial fibroblast cells, inflammatory macrophages and monocytes, suggesting that the regulatory 
variants in COMMD10 locus may be influencing the ABI or PAD via inflammatory and/or coagulation pathways, 
which is consistent with previously hypothesized roles for COMMD10. However, functional evaluation is needed to 
confirm the postulated underlying mechanisms. The co-localization analysis pointed to rs10062588 as a potential 
functional SNP in aortic artery and left ventricle heart tissues, however, the posterior probabilities were 0.31–0.40. 
HCHS/SOL group Index SNP Chr Allele A Allele B
HCHS/SOL MESA Hispanic MESA AA MESA EA
Beta p-value Beta p-value Beta p-value Beta p-value
Dominican rs6750426 2 G A 0.031 7.39E-08 −0.006 5.58E-01 −0.019 6.79E-01 −0.023 7.93E-01
Puerto Rican rs4466200 5 G A 0.024 3.40E-09 0.016 3.34E-01 0.074 2.16E-02 −0.037 8.81E-01
Puerto Rican rs7755533 6 G A 0.022 9.28E-08 0.014 3.73E-01 0.024 2.82E-01 0.043 1.02E-01
Central American rs6631478 X T C −0.024 7.02E-08 −0.118 2.22E-04 −0.012 3.52E-01 0.013 6.43E-01
Caribbean rs3133941 8 A G −0.018 1.78E-08 −0.032 2.50E-01 −0.04 1.27E-01 −0.001 4.94E-01
Table 3. Replication Results for Significant and Suggestive Loci for the ABI in Stratified Subgroup Analyses. 
*Allele A is the effect allele. All variants were imputed, and all were common (MAF range 0.11–0.48 across all 
variants and all ethnic groups) in MESA. MESA replication sample sizes were n = 1,447 (Hispanic), n = 1,613 
African American (AA), and n = 2,527 European American (EA). Rs113916643 was not available in MESA and 
is omitted from this table.
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This analysis is limited by the different populations between GTEx (European Ancestry) and HCHS/SOL, despite 
minor allele frequencies being quite similar (Supplementary Fig. S16).
The DMD locus on chromosome X replicated in MESA Hispanics for the ABI. Deletions, duplications, rear-
rangements, and point mutations in DMD, the dystrophin gene, have been strongly linked to Duchenne muscular 
dystrophy (DMD), Becker muscular dystrophy (BMD), and cardiomyopathy36–39. However, our functional anno-
tation results did not identify any regulatory features associated with rs6631478.
None of the previously reported associations in populations of European, African, or East Asian (Japanese) 
ancestries generalized to Hispanics/Latinos, which could be due to the persisting low coverage of imputed gen-
otypes using 1000 Genomes data, as well as the presence of genetic admixture. However, the stratified analysis 
revealed multiple associations with ABI, in specific Hispanic/Latino subgroups. These associations comprised 
largely common variants, and are therefore less likely to be statistical artifacts driven by outliers. In addition, 
these subgroup-specific associations were highly heterogeneous, as observed by comparing effect sizes and allele 
frequencies across Hispanic ethnic subgroups.
However, there is at least some evidence of common genetic basis at the regional level for ABI and PAD across 
race/ethnicities, with significant heterogeneity within each region. At the SYTL3 locus, we identified a SNP asso-
ciated with borderline PAD (rs317789, p < 10−6) in a close proximity (700 bp) to a previously reported associa-
tion with the ABI in Europeans (rs2171209), although rs317789 is not correlated with rs2171209 in European or 
Hispanic populations. Variants in SYTL3 have been previously associated with circulating lipoprotein(a) levels 
(Lp(a))40 which is a largely genetically regulated biomarker41. We have previously hypothesized that the asso-
ciation of SYTL3 with the ABI and PAD may be mediated through Lp(a) levels12; however, circulating Lp(a) is 
unfortunately also not available in the HCHS/SOL to test this hypothesis. Our results for SYTL3 also indicate that 
while the same loci may contribute to the underlying genetic architecture of PAD, heterogeneity within these loci 
and in ancestral background plays a substantial role.
This study has a few limitations. The ABI outcome is highly skewed, which may reduce power and increase type 
1 error of genetic association studies42. Moreover, more than half of the study participants have ABI > 1. It is unclear 
which factors determine variation of ABI in the range of ABI > 1, and some of these factors are likely arterial elastic 
properties, height, and weight43. However, in a sensitivity analysis reported in Supplementary Table S3, we tested all 
associations reported in Table 2, with added adjustment to height and weight, and the results were essentially the 
same. For PAD analysis, the low number of cases of this population-based sample, reduces power, compared to a 
potential case-control study that would specifically target PAD cases. This may reduce the power of ABI analysis as 
well. Another limitation is the small sample size, resulting in low statistical power. The largest, Mexican subgroup, 
had 2,619 individuals, and the pooled analysis had 7,589 individuals, which is considered low for a GWAS. Future 
analyses should leverage the admixture pattern for genetic discoveries via admixture mapping, which has reduced 
multiple testing burden and was useful in other genetic analyses in this cohort44–46, and combine the HCHS/SOL 
GWAS with analyses in other cohorts in meta-analysis. Another limitation is the large number of tests, considering 
the different traits and subgroups: we performed ABI (pooled and by subgroup), PAD, and borderline PAD analyses. 
Still, the analyses were well controlled in terms of inflation, resulting in only a handful of findings among all analyses.
Additional evidence of regional heterogeneity in common genetic loci was observed in our MESA replication 
analysis. Specifically, an exploratory regional replication analysis of all common SNPs available in MESA around 
the HCHS/SOL lead SNPs from the stratified ABI analysis, detected two PAD SNPs different from the lead in 
HCHS/SOL: in the DMD locus, rs77460337 was 14 bp away from the HCHS/SOL Central American ABI lead 
SNP, and at the COMMD10 locus, rs12520838 was 99,000 bp away from the HCHS/SOL Puerto Rican lead SNP. 
Overall, our generalization and replication results suggest there may be additional associations existing in both 
HCHS/SOL and MESA Hispanic populations, which may be detected once denser imputation panels are used, or 
whole genome sequencing data is available.
The current analysis detected multiple novel genetic variants associated with ABI in Hispanic/Latino ethnic 
subgroups from the HCHS/SOL. One of the lead SNPs in the DMD gene replicated in MESA Hispanics, despite 
the discovery being specific to Central Americans, and both the DMD and COMMD10 loci regionally replicated 
in MESA Hispanics, albeit with different MESA-specific lead SNPs. Our results suggest regional commonality, but 
significant heterogeneity at the regional level for genetic architecture underlying the ABI and PAD. Care should be 
taken in interpreting these results due to the large multiple testing burden and low sample sizes within the Hispanic/
Latino subgroups, and additional efforts for replication are needed, ideally, in diverse Hispanic/Latino populations. 
Another possible explanation for these results is that associated genotypes have different allele frequencies, and even 
different effect sizes, between ancestral populations (Europeans, Africans, Amerindians), and different admixture 
patterns in subpopulations of Hispanics/Latinos lead to different tag SNPs for the causal variants, and differences in 
power to discover these associations. Admixture mapping may help in revealing such insights. Future whole genome 
sequencing studies in diverse populations are important to facilitate better understanding and fine mapping of ABI/
PAD loci, and may inform the mystery of lack of generalization of ABI/PAD loci across populations, including loci 
reported here, and in previous studies of European Ancestry and Japanese individuals.
Data Availability
Genotype data of the HCHS/SOL and summary statistics from all discovery GWAS for ABI, PAD, borderline 
PAD, and arterial stiffness can be requested via dbGaP study accession phs000880. Complete meta-data related to 
these analyses is recorded for reproducibility in the HCHS/SOL Genetic Analysis Center’s Integrated Computing 
and Tracking system (unique analysis IDs are provided in Supplementary Table S11 in the Supplementary Infor-
mation). Phenotype data can be requested via dbGaP study accession phs000810.
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